Fludarabine 50mg Powder For Solution For Injection Or Infusion

DRUG4 trials

Sponsors

Prinses Maxima Centrum voor Kinderoncologie B.V., Iovance Biotherapeutics Inc., Ospedale Pediatrico Bambino Gesu

Conditions

Acute Myeloid LeukemiaFramework for OptimizingMetastatic Non-Small-Cell Lung CancerNeoplasmRefiningand Unifying Management of HSCT in Pediatric ALL

Phase 2

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer

RecruitingCTIS2024-510778-26-00

Iovance Biotherapeutics Inc.Metastatic Non-Small-Cell Lung Cancer

Start: 2025-12-19Target: 115Updated: 2025-11-26

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Patients with Solid Tumors

Active, not recruitingCTIS2024-510779-39-00

Iovance Biotherapeutics Inc.Neoplasm

Start: 2018-12-19Target: 95Updated: 2026-01-21

Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL.

RecruitingCTIS2025-522052-13-00

Ospedale Pediatrico Bambino Gesuand Unifying Management of HSCT in Pediatric ALL, Framework for Optimizing, Refining

Start: 2025-12-24Target: 735Updated: 2025-11-24

Phase 3

CHIP-AML22 Master protocol: An open label complex clinical trial in newly diagnosed pediatric de novo AML patients – a study by the NOPHO-DB-SHIP consortium Master Protocol

RecruitingCTIS2023-504999-25-00

Prinses Maxima Centrum voor Kinderoncologie B.V.Acute Myeloid Leukemia

Start: 2023-07-14Target: 675Updated: 2025-08-14